drugset / Trial / NCT07166393

Valproic AcId for Traumatic BRAin INjury Trial

NCT07166393

RandomizedParallel-groupTriple-blindTreatment

Summary

The long-term goal of the clinical trial is to develop effective, safe, and easily administered life-saving treatments for patients with moderate to severe traumatic brain injury (TBI). Patients with moderate to severe TBI will randomly receive either: 1. Standard of care treatment and normal saline 2. Standard of care treatment and one dose of valproic acid (VPA) at a lower dose or a higher dose

Timeline

Start
2026-05
Primary completion
2030-02
Completion
2030-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Valproic Acid Small molecule 50 mg/kg Intravenous
Subject Valproic Acid Small molecule 100 mg/kg Intravenous